people who received laryngomicrosurgery for vocal polyps or nodules and without regional or systemic disorders were used as control subjects. Informed consent was obtained from all subjects. Table 1 summarizes the patients and control subjects studied herein, including gender, age and staging of carcinomatous status. The staging was according to the AJCC Staging System (1988).
Blood samples
Blood samples were obtained before definite treatment was begun.
Blood was centifuged at 1500 r.p.m. for 15 min, at room temperature. Finally, serum was separated and frozen until further use.
Immunoassay
The concentration of sICAM-1, sE-selectin and sVCAM-1 in serum was determined by enzyme-linked immunoassay kits (ELISA) from R&D Systems (Minneapolis, MN, USA), and were used according to the manufacturer's instructions. The sensitivities were 7 ng ml -1 for sICAM-1, 2 ng ml -1 for sE-selectin and 100 ng ml -1 for sVCAM-1.
Statistical analysis
The statistical significance was evaluated with Student's t-test. A P-value of less than 0.05 was deemed statistically significant. Table 2 , sICAM-1, sE-selectin and sVCAM-1 in the area of nasopharyngeal cancer, sE-selectin in oral cancer, and sEselectin and sVCAM-1 in laryngeal cancer are significantly higher than those in control subjects, although the sICAM-1 in laryngeal cancer is significantly lower. According to the staging systems, the status of these malignancies was divided into early (stage I and II) and late (stage III and IV) stages. sICAM-1, sE-selectin and sVCAM-1 do not differ in terms of concentrations between the early and the late stages of nasopharyngeal, oral and laryngeal carcinoma (Table 3) .
RESULTS
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DISCUSSION
The cellular source and the mechanisms for releasing the soluble components of these endothelial adhesion molecules, although not well known, could involve either shedding or enzymatic cleavage from endothelial cells, leucocyte surfaces or tumour cells. Previous works have indicated that the cellular expression of ICAM-1 on normal and malignant epithelial tissue including melanoma cell lines (Natali et al, 1990; Becker et al, 1991; Giavazzi et al, 1992) and renal cell lines (Tomita et al, 1990) can be augmented by γ-interferon (IFN-γ), interleukin 1 (IL-1) and tumour necrosis factor (TNF-α) (Maio et al, 1989; Vanky et al, 1990; Azuma et al, 1992) . Notably, TNF can cause the release of ICAM-1, VCAM-1 and Eselectin from endothelial cells of human umbilical vein . IFN-γ can also induce expression and shedding of ICAM-1 from gastric cell lines (Harning et al, 1991) . However, the clinical significance and the interaction between these molecules still remain relatively unknown. Yamamoto et al (1994) measured the circulating ICAM-1 in the sera of oral diseases, indicating that the circulating ICAM-1 was not elevated in the sera of oral squamous cell carcinoma patients. Similarly, in this series, the circulating ICAM-1 was not elevated in the sera of patients with oral cancer and laryngeal cancer in this series. However, circulating ICAM-1, E-selectin and VCAM-1 were elevated in the sera of patients with nasopharyngeal carcinoma (NPC), i.e. a common human epithelial carcinoma in South-East Asia. The discrepancy of the level of soluble ICAM-1 among these three groups of patients of head and neck carcinomas might be attributed to either the different immunological reaction profiles or a cell-specific response. According to previous investigators, soluble IL-2 receptor, IFN-γ and TNF-α were elevated in NPC patients (Hsu et al, 1991; Kuo et al, 1994) . These factors might contribute towards the cellular expression and shedding of ICAM-1, E-selectin and VCAM-1 as shown in these NPC patients.
VCAM-1 and E-selectin are largely absent on the endothelium of normal tissue vessels (Kuzu et al, 1993) . VCAM-1 is present on lymphoid dendritic cells, some tissue macrophages and renal parietal epithelium in addition to activated endothelial cells (Rice et al, 1991) . VCAM-1 might be involved in metastasis of melanoma (Rice et al, 1989) . Interestingly, elevated levels of sVCAM-1 were noted in several human malignancies such as in the ovary and breast, outside of the head and neck region (Banks et al, 1993) . Expression of E-selectin is endothelium-specific (Bevilacqua and Nelson, 1993) , and E-selectin-mediated adhesion of colon carcinoma and head and neck squamous cell carcinoma cells to endothelium is suggested to be associated with metastasis (Lauri et al, 1991; Wenzel et al, 1995) . Soluble E-selectin is evaluated as a marker for endothelial damage after activation by cytokines (Gearing and Newman, 1993) , the levels are higher in ovarian, breast and gastrointestinal cancers (Banks et al, 1993) . The increased levels of sE-selectin in the patients sera of NPC, oral and laryngeal cancers in this series might be attributed to the shedding of endothelially bound E-selectin in the tumour tissues. Thus, this E-selectin might be a potential marker for tumour invasiveness or angiogenesis in head and neck cancer. The differences arising between the levels of sICAM-1, sVCAM-1 and sE-selectin in these three head and neck cancers might be attributed to the nature of the tumour, cytokines responsible for adhesion molecule expression, shedding regardless of whether they are tumour-derived or derived from surrounding host tissues, and kinetics of expression and shedding.
The progression of a tumour from benign delimited proliferation to invasive and metastasic growth depends on angiogenesis, enhanced extracellular matrix degradation via tumour-and hostsecreted proteases, tumour cell migration and modulation of tumour cell adhesion. Each individual component is multifaceted (Price et al, 1997) . The fact that sICAM-1, sVCAM-1 and sEselectin did not significantly differ in terms of levels between early and late stages of these three head and neck cancers accounts for why these soluble adhesion molecules appear not to be the only factor in their tumour progression.
Immunologically, shedding of adhesion molecules by activated endothelial cells and tumour cells might not only block their counter ligands on immunocompetent cells, but also allow the tumour cells to escape from surveillance by cytotoxic T-cells and natural killer cells, thereby promoting metastasis. These shedding adhesion molecules might also prevent tumour cells from adhering to endothelial cells during extravasation. Future investigations on the function and interaction of these adhesion molecules may clarify the mechanism of tumour progression and metastasis.
